Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | NPEPPS | P55786 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 4/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | PPARG | P37231 | 2/20 | 0.38 |
| ▸ | PPARA | Q07869 | 2/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6069900 | 0.76 | TSHR (0.57) | CYP3A4CYP2C19ALDH1A1L3MBTL1TSHR | |
| SCHEMBL6069907 | 0.76 | TSHR (0.57) | CYP3A4CYP2C19ALDH1A1L3MBTL1TSHR | |
| SCHEMBL6069915 | 0.76 | TSHR (0.57) | CYP3A4CYP2C19ALDH1A1L3MBTL1TSHR | |
| SCHEMBL13699311 | 0.68 | TSHR (0.48) | CYP3A4CYP2C19ALDH1A1L3MBTL1TSHR | |
| SCHEMBL13699230 | 0.68 | TSHR (0.48) | CYP3A4CYP2C19ALDH1A1L3MBTL1TSHR | |
| SCHEMBL13699375 | 0.68 | CA12 (0.50) | ALDH1A1L3MBTL1MEN1KMT2APOLB | |
| SCHEMBL13699279 | 0.68 | CA12 (0.50) | ALDH1A1L3MBTL1MEN1KMT2APOLB | |
| SCHEMBL13699280 | 0.68 | CA12 (0.50) | ALDH1A1L3MBTL1MEN1KMT2APOLB | |
| SCHEMBL17490913 | 0.68 | ALDH1A1 (0.56) | CYP3A4CYP2C19ALDH1A1HTTL3MBTL1 | |
| SCHEMBL7804819 | 0.67 | MEN1 (0.55) | ALDH1A1MEN1KMT2APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120040916-A1 | MOLECULAR INHIBITORS OF THE WNT/BETA-CATENIN PATHWAY | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2012-02-16 | — | — | US | disclosed |
| US-20120040916-A1 | MOLECULAR INHIBITORS OF THE WNT/BETA-CATENIN PATHWAY | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2012-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120040916-A1 | MOLECULAR INHIBITORS OF THE WNT/BETA-CATENIN PATHWAY | WNT1, CTNNB1, WNT3A | CYP3A4 2995/4885CYP2C19 3624/4885ALDH1A1 1645/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.